Development Pipeline

Esperion is a late-stage pharmaceutical company that specializes in developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Bempedoic acid, the Company’s lead product candidate, is currently in global Phase 3 clinical development. Esperion owns the exclusive worldwide rights to bempedoic acid.

Compound
Indication
  • Phase Ph1
  • Ph2
  • Ph3
Lowering Elevated LDL-C
  • Ph3
CVD Risk Reduction
  • Ph3
Lowering Elevated LDL-C
  • Ph3
CVD Risk Reduction
  • Ph3